Publication Information

{'id': 'https://openalex.org/W2390395321', 'doi': None, 'title': 'Plasma drug level of risperidone and its clinical significance', 'display_name': 'Plasma drug level of risperidone and its clinical significance', 'publication_year': 2001, 'publication_date': '2001-01-01', 'ids': {'openalex': 'https://openalex.org/W2390395321', 'mag': '2390395321'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://en.cnki.com.cn/Article_en/CJFDTOTAL-ZXYZ200106019.htm', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764576346', 'display_name': 'Chinese New Drugs Journal', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5023918475', 'display_name': 'Zhiqin Gao', 'orcid': 'https://orcid.org/0000-0002-0695-0627'}, 'institutions': [], 'countries': [], 'is_corresponding': True, 'raw_author_name': 'Gao Zhi-qin', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': ['https://openalex.org/A5023918475'], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 1, 'citation_normalized_percentile': {'value': 0.431969, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 59, 'max': 66}, 'biblio': {'volume': None, 'issue': None, 'first_page': None, 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T14028', 'display_name': 'Healthcare and Venom Research', 'score': 0.9737, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T14028', 'display_name': 'Healthcare and Venom Research', 'score': 0.9737, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/active-metabolite', 'display_name': 'Active metabolite', 'score': 0.7229117}, {'id': 'https://openalex.org/keywords/clinical-efficacy', 'display_name': 'Clinical efficacy', 'score': 0.43213806}, {'id': 'https://openalex.org/keywords/plasma-levels', 'display_name': 'Plasma levels', 'score': 0.41166118}], 'concepts': [{'id': 'https://openalex.org/C2780057945', 'wikidata': 'https://www.wikidata.org/wiki/Q412443', 'display_name': 'Risperidone', 'level': 3, 'score': 0.9761447}, {'id': 'https://openalex.org/C2777477808', 'wikidata': 'https://www.wikidata.org/wiki/Q407595', 'display_name': 'Metabolite', 'level': 2, 'score': 0.76264524}, {'id': 'https://openalex.org/C149151106', 'wikidata': 'https://www.wikidata.org/wiki/Q4677569', 'display_name': 'Active metabolite', 'level': 3, 'score': 0.7229117}, {'id': 'https://openalex.org/C2776412080', 'wikidata': 'https://www.wikidata.org/wiki/Q7431605', 'display_name': 'Schizophrenia (object-oriented programming)', 'level': 2, 'score': 0.63510907}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.6113135}, {'id': 'https://openalex.org/C2780035454', 'wikidata': 'https://www.wikidata.org/wiki/Q8386', 'display_name': 'Drug', 'level': 2, 'score': 0.60723424}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.5151397}, {'id': 'https://openalex.org/C3020079912', 'wikidata': 'https://www.wikidata.org/wiki/Q3918988', 'display_name': 'Plasma concentration', 'level': 2, 'score': 0.5000546}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.4352162}, {'id': 'https://openalex.org/C2992053201', 'wikidata': 'https://www.wikidata.org/wiki/Q2585693', 'display_name': 'Clinical efficacy', 'level': 2, 'score': 0.43213806}, {'id': 'https://openalex.org/C3454156', 'wikidata': 'https://www.wikidata.org/wiki/Q1144241', 'display_name': 'Side effect (computer science)', 'level': 2, 'score': 0.41241345}, {'id': 'https://openalex.org/C3017575891', 'wikidata': 'https://www.wikidata.org/wiki/Q3918988', 'display_name': 'Plasma levels', 'level': 2, 'score': 0.41166118}, {'id': 'https://openalex.org/C15744967', 'wikidata': 'https://www.wikidata.org/wiki/Q9418', 'display_name': 'Psychology', 'level': 0, 'score': 0.3480695}, {'id': 'https://openalex.org/C118552586', 'wikidata': 'https://www.wikidata.org/wiki/Q7867', 'display_name': 'Psychiatry', 'level': 1, 'score': 0.24407083}, {'id': 'https://openalex.org/C41008148', 'wikidata': 'https://www.wikidata.org/wiki/Q21198', 'display_name': 'Computer science', 'level': 0, 'score': 0.0}, {'id': 'https://openalex.org/C199360897', 'wikidata': 'https://www.wikidata.org/wiki/Q9143', 'display_name': 'Programming language', 'level': 1, 'score': 0.0}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://en.cnki.com.cn/Article_en/CJFDTOTAL-ZXYZ200106019.htm', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764576346', 'display_name': 'Chinese New Drugs Journal', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': None, 'host_organization_name': None, 'host_organization_lineage': [], 'host_organization_lineage_names': [], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'score': 0.8, 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3207213207', 'https://openalex.org/W2791629423', 'https://openalex.org/W2467955913', 'https://openalex.org/W2465684388', 'https://openalex.org/W2413334594', 'https://openalex.org/W2388825225', 'https://openalex.org/W2386304628', 'https://openalex.org/W2378616719', 'https://openalex.org/W2368325287', 'https://openalex.org/W2366583741', 'https://openalex.org/W2361037870', 'https://openalex.org/W2168445796', 'https://openalex.org/W2145707328', 'https://openalex.org/W2116935347', 'https://openalex.org/W2086762066', 'https://openalex.org/W2071330308', 'https://openalex.org/W1994870822', 'https://openalex.org/W1994627117', 'https://openalex.org/W1969738024', 'https://openalex.org/W1439445912'], 'abstract_inverted_index': {'Objective:To': [0], 'observe': [1], 'the': [2, 9, 54, 80, 92], 'relationship': [3], 'among': [4], 'oral': [5], 'dose,plasma': [6], 'drug': [7, 41, 100, 165], 'level,and': [8], 'efficacy': [10, 152], 'and': [11, 27, 45, 59, 68, 75, 104, 110, 125, 135, 146, 153, 161, 169], 'side': [12, 154], 'effects': [13], 'of': [14, 43, 56, 78, 82, 91, 102, 140, 156, 167], 'risperidone.Methods:The': [15], 'controlled': [16], 'study': [17], 'was': [18, 70, 87, 94], 'conducted': [19], 'in': [20, 72, 98, 118, 149], '38': [21], 'patients': [22], 'with': [23, 143], 'schizophrenia.They': [24], 'were': [25, 63], 'randomly': [26], 'equally': [28], 'divided': [29], 'to': [30], 'receive': [31], '2': [32, 108], 'or': [33], '4': [34, 111], 'mg': [35, 109, 112], 'risperidone': [36, 44, 103, 124, 141, 157, 168], 'for': [37, 84, 123, 138], '8': [38], 'weeks.The': [39], 'plasma': [40, 99, 164], 'level': [42, 101], 'its': [46, 105, 126, 170], 'active': [47, 127, 171], 'metabolite,9-hydroxyrisperidone,were': [48], 'measured': [49], 'by': [50, 163], 'HPLC': [51], 'method': [52, 137], 'at': [53, 65], 'end': [55], 'week': [57, 66], '2,4': [58], '8.The': [60], 'PANSS,CGI,TESS,and': [61], 'ESRS': [62], 'evaluated': [64], '1,2,4,6': [67], '8.Results:Risperidone': [69], 'effective': [71, 120, 134], 'both': [73], 'positive': [74, 85], 'negative': [76], 'symptoms': [77], 'schizophrenia,but': [79], 'onset': [81], 'action': [83], 'symptom': [86], 'quicker': [88], 'than': [89], 'that': [90], 'negative.There': [93], 'a': [95], 'significant': [96, 116], 'difference': [97, 117], 'metabolite': [106, 128], 'between': [107], 'groups': [113], 'but': [114], 'no': [115], 'efficacy.The': [119], 'dose': [121, 150], 'range': [122], 'may': [129], 'be': [130, 159], '30～45': [131], 'ng·mL': [132], '-1.Conclusion:The': [133], 'safe': [136], 'medication': [139], 'starts': [142], 'small': [144], 'dose(2～4mg)': [145], 'then': [147], 'increases': [148], 'gradually.The': [151], 'effect': [155], 'can': [158], 'predicated': [160], 'prevented': [162], 'concentration': [166], 'metabolite.': [172]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2390395321', 'counts_by_year': [], 'updated_date': '2024-12-14T10:08:42.230807', 'created_date': '2016-06-24'}